An Italian neurosurgeon who operated on an 18-year-old girl who died after receiving a Covid vaccine claimed he’d never worked on a brain so severely and uncontrollably inflamed. 18-year-old Sestri Levante resident Camilla Canepa received the AstraZeneca vaccine on an “open day” on May 25.
By June 3, she was admitted to an emergency room suffering a headache and photophobia, or extreme sensitivity to light. A CT scan failed to find evidence of a thrombosis and Canepa was discharged. Canepa returned to the emergency room on June 5 suffering “motor deficits,” according to Italy24News.com.
Once the thrombosis was discovered, Canepa was transferred to San Martino Hospital in Genova where surgeon Alessandro d’Andrea diagnosed the issue. Speaking to Italian media Il Piccolo, Gianluigi Zona, the director of the neurological and neuro-traumatological clinic of the San Martino hospital, described being baffled by the severe thrombosis seen in images of Canepa’s brain.
“I am not a virologist or an epidemiologist or a coroner but, in the face of the picture I saw in that girl’s head, it is clear that we are dealing with something not normal,” Zona described. “We opted for a decompression craniotomy, the skull opened to relieve internal pressure,” Zona said. However, according to the doctors, the brain would not drain and instead soaked up blood, something Zona said he’d never witnessed before.
“All the venous sinuses were blocked by thrombus, a scenario that I had never seen in many years of this profession. “
“You have to imagine the venous sinus as the river in the center of a valley in which several streams converge,” Zona described. “If a dam is built at the center of the watercourse, the river swells and at that point the tributaries are unable to discharge, with the result that the upstream pressure rises.”
Canepa’s parents claim “Camilla had no disease” prior to the vaccine as an investigation has been launched into the bizarre death. Canepa’s death as well as that of several others prompted Italian health officials to halt distribution of the AstraZeneca to people under 60 last month.
“AstraZeneca will only be used for people over 60,” stated Italy COVID commissioner Francesco Figliuolo.
“The risk-benefit assessment has changed.”